Page 17 - 《中国药房》2026年8期

induced thrombocytopenia[J]. Am J Hematol，2011，86 patients with ventricular assist devices[J]. JTCVS Open，
（3）：267-272. 2024，20：132-140.
[35] YARBROUGH P M，VAREDI A，WALKER A，et al. Arga- [49] YOUNG G，TARANTINO M D，WOHRLEY J，et al. Pi‐
troban dose reductions for suspected heparin-induced lot dose-finding and safety study of bivalirudin in infants＜
thrombocytopenia complicated by Child-Pugh class C 6 months of age with thrombosis[J]. J Thromb Haemost，
liver disease[J]. Ann Pharmacother，2012，46（11）：e30. 2007，5（8）：1654-1659.
[36] CETTA F，GRAHAM L C，WRONA L L，et al. Argatro‐ [50] RAYAPUDI S，TORRES A Jr，DESHPANDE G G，et al.
ban use during pediatric interventional cardiac catheteriza‐ Bivalirudin for anticoagulation in children[J]. Pediatr
tion[J]. Cathet Cardio Intervent，2004，61（1）：147-149. Blood Cancer，2008，51（6）：798-801.
[37] HASIJA S，TALWAR S，MAKHIJA N，et al. Randomized [51] 刘奉琴，陈星. 儿童肺血栓栓塞症的抗凝治疗进展[J]. 医
controlled trial of heparin versus bivalirudin anticoagula‐ 学综述，2021，27（6）：1157-1164.
tion in acyanotic children undergoing open heart surgery [52] BUCK M L. Bivalirudin as an alternative to heparin for
[J]. J Cardiothorac Vasc Anesth，2018，32（6）：2633-2640. anticoagulation in infants and children[J]. J Pediatr Phar‐
[38] LI N，HAN J D. Clinical study of argatroban for pre- macol Ther，2015，20（6）：408-417.
venting vascular thrombosis in the early period after pediatric [53] O’BRIEN S H，YEE D L，LIRA J，et al. UNBLOCK：an
living-related donor liver transplantation[J]. Pediatr Trans‐ open-label，dose-finding，pharmacokinetic and safety
plant，2020，24（2）：e13654. study of bivalirudin in children with deep vein thrombosis
[39] FORBES T J，HIJAZI Z M，YOUNG G，et al. Pediatric [J]. J Thromb Haemost，2015，13（9）：1615-1622.
catheterization laboratory anticoagulation with bivalirudin [54] ZENG Q，FU Q N，LI F H，et al. Early initiation of arga-
[J]. Cathet Cardio Intervent，2011，77（5）：671-679. troban therapy in the management of acute superior mes‐
[40] MA M，LIANG S C，ZHU J B，et al. The efficacy and enteric venous thrombosis[J]. Exp Ther Med，2017，13
safety of bivalirudin versus heparin in the anticoagulation （4）：1526-1534.
therapy of extracorporeal membrane oxygenation：a sys‐ [55] WU H X，TANG Y J，XIONG X F，et al. Successful appli‐
tematic review and meta-analysis[J]. Front Pharmacol， cation of argatroban during VV-ECMO in a pregnant pa‐
2022，13：771563. tient complicated with ARDS due to severe tuberculosis：a
[41] LIU L Y，LIU F，TAN J X，et al. Bivalirudin versus hepa‐ case report and literature review[J]. Front Pharmacol，
rin in adult and pediatric patients with extracorporeal 2022，13：866027.
membrane oxygenation therapy：a systematic review and [56] JYOTI A，MAHESHWARI A，DANIEL E，et al. Bivaliru‐
meta-analysis[J]. Pharmacol Res，2022，177：106089. din in venovenous extracorporeal membrane oxygenation
[42] HAMZAH M，JARDEN A M，EZETENDU C，et al. [J]. J Extra Corpor Technol，2014，46（1）：94-97.
Evaluation of bivalirudin as an alternative to heparin for [57] JESKE W P，FAREED J，HOPPENSTEADT D A，et al.
systemic anticoagulation in pediatric extracorporeal mem‐ Pharmacology of argatroban[J]. Expert Rev Hematol，
brane oxygenation[J]. Pediatr Crit Care Med，2020，21 2010，3（5）：527-539.
（9）：827-834. [58] SCIULLI T M，MAURO V F. Pharmacology and clinical
[43] RANUCCI M，BALLOTTA A，KANDIL H，et al. use of bivalirudin[J]. Ann Pharmacother，2002，36（6）：
Bivalirudin-based versus conventional heparin anticoagu‐ 1028-1041.
lation for postcardiotomy extracorporeal membrane oxy‐ [59] GREINACHER A，THIELE T，SELLENG K. Reversal of
genation[J]. Crit Care，2011，15（6）：R275. anticoagulants：an overview of current developments[J].
[44] 刘 桂 良 ，王 敏 ，庞 小 容 ，等 . 阿 加 曲 班 抗 凝 在 儿 童 Thromb Haemost，2015，113（5）：931-942.
VA-ECMO 中的应用效果分析[J]. 中国临床新医学， [60] KOSCIELNY J，RUTKAUSKAITE E，SUCKER C，et al.
2023，16（7）：684-689. How do I reverse oral and parenteral anticoagulants? [J].
[45] VANDERPLUYM C J，CANTOR R S，MACHADO D，et Hamostaseologie，2020，40（2）：201-213.
al. Utilization and outcomes of children treated with direct [61] LEVI M，LEVY J H，ANDERSEN H F，et al. Safety of re‐
thrombin inhibitors on paracorporeal ventricular assist de‐ combinant activated factor Ⅶ in randomized clinical trials
vice support[J]. ASAIO J，2020，66（8）：939-945. [J]. N Engl J Med，2010，363（19）：1791-1800.
[46] FRENIERE V，SALERNO D M，CORBO H，et al. Bivali‐ [62] YOUNG G，YONEKAWA K E，NAKAGAWA P A，et al.
rudin compared to heparin as the primary anticoagulant in Recombinant activated factor Ⅶ effectively reverses the
pediatric berlin heart recipients[J]. ASAIO J，2023，69（5）： anticoagulant effects of heparin，enoxaparin，fondaparinux，
e205-e211. argatroban，and bivalirudin ex vivo as measured using
[47] BURSTEIN D，KIMMEL S，PUTT M，et al. Cost- thromboelastography[J]. Blood Coagul Fibrinolysis，2007，
effectiveness of bivalirudin in pediatric ventricular assist 18（6）：547-553.
devices[J]. J Heart Lung Transplant，2023，42（3）：390-397. （收稿日期：2025-11-09 修回日期：2026-03-17）
[48] ADDERLEY J，PIDBOROCHYNSKI T，BUCHHOLZ H， （编辑：张元媛）
et al. Risk factors for thromboembolic events in pediatric

中国药房 2026年第37卷第8期 China Pharmacy 2026 Vol. 37 No. 8 · 975 ·